HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
amediplase
a recombinant chimeric plasminogen activator, consisting of the kringle 2 domain from the A-chain of tissue plasminogen activator (t-PA) and the carboxy terminal region of pro-urokinase
Also Known As:
CGP 42935; K2tu-PA; MEN 9036
Networked:
4
relevant articles (
0
outcomes,
2
trials/studies)
Bio-Agent Context: Research Results
Enzymes and Coenzymes: 1
Enzymes: 152586
Hydrolases: 2166
Peptide Hydrolases: 23957
Serine Proteases: 3726
Serine Endopeptidases: 11
Tissue Plasminogen Activator: 10595
amediplase: 4
Urokinase-Type Plasminogen Activator: 5828
amediplase: 4
Endopeptidases: 633
Serine Endopeptidases: 11
Tissue Plasminogen Activator: 10595
amediplase: 4
Urokinase-Type Plasminogen Activator: 5828
amediplase: 4
Amino Acids, Peptides, and Proteins: 1
Proteins: 484843
Blood Proteins: 12459
Blood Coagulation Factors: 5376
Plasminogen Activators: 5174
Tissue Plasminogen Activator: 10595
amediplase: 4
Urokinase-Type Plasminogen Activator: 5828
amediplase: 4
Recombinant Proteins: 2754
amediplase: 4
Biological Factors: 2472
Blood Coagulation Factors: 5376
Tissue Plasminogen Activator: 10595
amediplase: 4
Experts
1.
Doggrell, Sheila A
: 1 article (03/2004)
Related Diseases
1.
Thrombosis (Thrombus)
05/03/1993 - "
The concentration producing 50% lysis of blood clots in 3 h was 0.5 microgram/ml for K2tu-PA and 1 microgram/ml for FK2tu-PA, as compared to 0.5 microgram/ml and > 2 micrograms/ml for t-PA and scu-PA, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)
"
08/02/1993 - "
The aim of this study was to compare the effects of bolus doses of recombinant t-PA (rt-PA) and K2tu-PA, on: 1) lysis of performed thrombi (fibrinolysis), 2) accretion of new fibrin on pre-existing thrombi during fibrinolysis (thrombus growth), 3) thrombolysis as assessed by reduction of thrombus weight and 4) systemic plasma proteolysis and blood loss from a standard wound.
"
03/01/2004 - "
Amediplase, a chimeric protein containing functional domains of both tissue plasminogen activator and pro-urokinase plasminogen activator, is under development by Menarini for the potential treatment of thrombosis.
"
2.
Wounds and Injuries (Trauma)
08/02/1993 - "
The aim of this study was to compare the effects of bolus doses of recombinant t-PA (rt-PA) and K2tu-PA, on: 1) lysis of performed thrombi (fibrinolysis), 2) accretion of new fibrin on pre-existing thrombi during fibrinolysis (thrombus growth), 3) thrombolysis as assessed by reduction of thrombus weight and 4) systemic plasma proteolysis and blood loss from a standard wound.
"
3.
Myocardial Infarction
01/01/2002 - "
Menarini is currently investigating amediplase in phase III clinical trials in Europe as a thrombolytic given as a single bolus to patients with myocardial infarction.
"
Related Drugs and Biologics
1.
Fibrin
2.
Proteins (Proteins, Gene)
3.
Plasminogen Activators (Plasminogen Activator)
4.
Tissue Plasminogen Activator (Alteplase)
5.
saruplase